Xilin Wu

Nanjing, 210093, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

A rationally designed cocktail of nanobodies elicited by heterologous vaccination confers protection against SFTSV in preclinical models.

A rationally designed cocktail of nanobodies elicited by heterologous vaccination confers protection against SFTSV in preclinical models.

Journal: Science translational medicine
Published: November 19, 2025

Pharmacokinetic-pharmacodynamic modeling of a highly potent and broadly neutralizing anti-CD4 trimeric nanobody to inhibit HIV-1 infection.

Pharmacokinetic-pharmacodynamic modeling of a highly potent and broadly neutralizing anti-CD4 trimeric nanobody to inhibit HIV-1 infection.

Journal: Microbiology spectrum
Published: September 19, 2025

Next-Generation Sequencing and Proteomics-Enabled Approach for Rapid and High-Throughput Isolation of Virus-Neutralizing Nanobodies.

Next-Generation Sequencing and Proteomics-Enabled Approach for Rapid and High-Throughput Isolation of Virus-Neutralizing Nanobodies.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 22, 2024

Structure defining of ultrapotent neutralizing nanobodies against MERS-CoV with novel epitopes on receptor binding domain.

Structure defining of ultrapotent neutralizing nanobodies against MERS-CoV with novel epitopes on receptor binding domain.

Journal: PLoS pathogens
Published: May 16, 2024

Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration.

Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration.

Journal: Nature communications
Published: October 30, 2023

Dauricine interferes with SARS-CoV-2 variants infection by blocking the interface between RBD and ACE2.

Dauricine interferes with SARS-CoV-2 variants infection by blocking the interface between RBD and ACE2.

Journal: International journal of biological macromolecules
Published: September 08, 2023

Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody.

Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody.

Journal: EMBO molecular medicine
Published: September 04, 2023

Development of functional anti-Gn nanobodies specific for SFTSV based on next-generation sequencing and proteomics.

Development of functional anti-Gn nanobodies specific for SFTSV based on next-generation sequencing and proteomics.

Journal: Protein science : a publication of the Protein Society
Published: April 02, 2022

Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22).

Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22).

Journal: Frontiers in immunology
Published: January 29, 2022

Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer.

Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer.

Journal: Frontiers in immunology
Published: March 09, 2021

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.

Journal: Cell reports
Published: March 03, 2021

AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia.

AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia.

Journal: Blood cancer journal
Published: March 01, 2021
Showing 1-12 of 20

Last Updated: 09/26/2026